{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:53:59Z","timestamp":1772726039132,"version":"3.50.1"},"reference-count":81,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Background :<\/jats:title>\n<jats:p>Recent studies suggested that patients with coronavirus disease 2019 (COVID-19) who use\nrenin-angiotensin system (RAS) inhibitors have an increased risk of respiratory failure and death. The hypothesis was that\nangiotensin-converting enzyme inhibitor (ACEIs) or angiotensin receptor blocker (ARBs) may up-regulate ACE2\nexpression that is used as receptor for viral entry into cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The purpose of this review is to discuss the existing evidence on the interaction between COVID-19 infection,\nACE2 and ACEIs or ARBs and to examine the main implications for clinical practice. In addition, novel therapeutic\nstrategies for blocking ACE2-mediated COVID-19 infection will be displayed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods :<\/jats:title>\n<jats:p> We performed a comprehensive review of the literature to identify data from clinical and experimental studies\nfor the association between COVID-19 infection, ACE2 and RAS inhibition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The current clinical and experimental evidence for ACEIs or ARBs to facilitate severe acute respiratory distress\nsyndrome-coronavirus-2 (SARS-CoV-2) is insufficient to suggest discontinuing these drugs. Several observational studies\narrive at the conclusion that the continued use of RAS inhibitors is unlike to be harmful in COVID-19-positive patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p> Further randomized trials are needed to answer definitely the question of whether RAS inhibitors are\nharmful or beneficial to patients with COVID-19.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573402117666210121100201","type":"journal-article","created":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T10:24:22Z","timestamp":1612088662000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System\nInhibition: Implications for Practice"],"prefix":"10.2174","volume":"18","author":[{"given":"Vasiliki","family":"Katsi","sequence":"first","affiliation":[{"name":"1st Department of Cardiology, \u2018Hippokration\u2019 General Hospital, National and Kapodistrian University of Athens,\nSchool of Medicine, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-3446","authenticated-orcid":true,"given":"George","family":"Pavlidis","sequence":"additional","affiliation":[{"name":"Emergency Department, \u2018Hippokration\u2019 General Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Charalambous","sequence":"additional","affiliation":[{"name":"Emergency Department, \u2018Hippokration\u2019 General Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tousoulis","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, \u2018Hippokration\u2019 General Hospital, National and Kapodistrian University of Athens,\nSchool of Medicine, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Toutouzas","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, \u2018Hippokration\u2019 General Hospital, National and Kapodistrian University of Athens,\nSchool of Medicine, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"Williams B.","year":"2018","unstructured":"Williams B.; Mancia G.; Spiering W.; Agabiti Rosei E.; Azizi M.; Burnier M.; Clement D.L.; Coca A.; de Simone G.; Dominiczak A.; Kahan T.; Mahfoud F.; Redon J.; Ruilope L.; Zanchetti A.; Kerins M.; Kjeldsen S.E.; Kreutz R.; Laurent S.; Lip G.Y.H.; McManus R.; Narkiewicz K.; Ruschitzka F.; Schmieder R.E.; Shlyakhto E.; Tsioufis C.; Aboyans V.; Desormais I.; 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018,39(33),3021-3104","journal-title":"Eur Heart J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12916-020-01533-w","volume":"18","author":"Fisher D.","year":"2020","unstructured":"Fisher D.; Heymann D.; Q","journal-title":"BMC Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"Zhou F.","year":"2020","unstructured":"Zhou F.; Yu T.; Du R.; Fan G.; Liu Y.; Liu Z.; Xiang J.; Wang Y.; Song B.; Gu X.; Guan L.; Wei Y.; Li H.; Wu X.; Xu J.; Tu S.; Zhang Y.; Chen H.; Cao B.; Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020,395(10229),1054-1062","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","volume":"25","author":"Turner A.J.","year":"2004","unstructured":"Turner A.J.; Hiscox J.A.; Hooper N.M.; ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004,25(6),291-294","journal-title":"Trends Pharmacol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"Li W.","year":"2003","unstructured":"Li W.; Moore M.J.; Vasilieva N.; Sui J.; Wong S.K.; Berne M.A.; Somasundaran M.; Sullivan J.L.; Luzuriaga K.; Greenough T.C.; Choe H.; Farzan M.; Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003,426(6965),450-454","journal-title":"Nature"},{"key":"ref=6","year":"2020","unstructured":"Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers European Society of Cardiology2020 www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang","journal-title":"Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers"},{"key":"ref=7","year":"2020","unstructured":"HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 American College of Cardiology2020 www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19","journal-title":"HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"Vaduganathan M.","year":"2020","unstructured":"Vaduganathan M.; Vardeny O.; Michel T.; McMurray J.J.V.; Pfeffer M.A.; Solomon S.D.; Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020,382(17),1653-1659","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41440-020-0515-0","volume":"43","author":"Shibata S.","year":"2020","unstructured":"Shibata S.; Arima H.; Asayama K.; Hoshide S.; Ichihara A.; Ishimitsu T.; Kario K.; Kishi T.; Mogi M.; Nishiyama A.; Ohishi M.; Ohkubo T.; Tamura K.; Tanaka M.; Yamamoto E.; Yamamoto K.; Itoh H.; Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res 2020,43(10),1028-1046","journal-title":"Hypertens Res"},{"key":"ref=10","author":"Ghazi L","year":"2017","unstructured":"Ghazi L; Drawz P; Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. F1000Res 6 pii: F1000 Faculty Rev-297 2017","journal-title":"F1000Res 6 pii: F1000 Faculty Rev-297"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/256294","volume":"2012","author":"Tikellis C.","year":"2012","unstructured":"Tikellis C.; Thomas M.C.; Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012,2012","journal-title":"Int J Pept"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","volume":"40","author":"Tan W.S.D.","year":"2018","unstructured":"Tan W.S.D.; Liao W.; Zhou S.; Mei D.; Wong W.F.; Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol 2018,40,9-17","journal-title":"Curr Opin Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1253\/circj.CJ-12-1544","volume":"77","author":"Kuba K.","year":"2013","unstructured":"Kuba K.; Imai Y.; Penninger J.M.; Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J 2013,77(2),301-308","journal-title":"Circ J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.micinf.2013.08.003","volume":"15","author":"Perlot T.","year":"2013","unstructured":"Perlot T.; Penninger J.M.; ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect 2013,15(13),866-873","journal-title":"Microbes Infect"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","volume":"128","author":"Kuba K.","year":"2010","unstructured":"Kuba K.; Imai Y.; Ohto-Nakanishi T.; Penninger J.M.; Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther 2010,128(1),119-128","journal-title":"Pharmacol Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.cellsig.2014.06.011","volume":"26","author":"Balakumar P.","year":"2014","unstructured":"Balakumar P.; Jagadeesh G.; A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cell Signal 2014,26(10),2147-2160","journal-title":"Cell Signal"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00041433-200210000-00006","volume":"13","author":"Strawn W.B.","year":"2002","unstructured":"Strawn W.B.; Ferrario C.M.; Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002,13(5),505-512","journal-title":"Curr Opin Lipidol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"Dandona P.","year":"2007","unstructured":"Dandona P.; Dhindsa S.; Ghanim H.; Chaudhuri A.; Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007,21(1),20-27","journal-title":"J Hum Hypertens"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4172\/2576-1471.1000134","volume":"2","author":"Chappell M.C.","year":"2017","unstructured":"Chappell M.C.; Al Zayadneh E.M.; Angiotensin-(1-7) and the regulation of anti-fibrotic signaling pathways. J Cell Signal 2017,2(1),134","journal-title":"J Cell Signal"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tem.2008.01.003","volume":"19","author":"Carey R.M.","year":"2008","unstructured":"Carey R.M.; Padia S.H.; Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008,19(3),84-87","journal-title":"Trends Endocrinol Metab"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.pharmthera.2008.08.009","volume":"120","author":"Jones E.S.","year":"2008","unstructured":"Jones E.S.; Vinh A.; McCarthy C.A.; Gaspari T.A.; Widdop R.E.; AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008,120(3),292-316","journal-title":"Pharmacol Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcdd6020014","volume":"6","author":"Nehme A.","year":"2019","unstructured":"Nehme A.; Zouein F.A.; Zayeri Z.D.; Zibara K.; An update on the tissue renin angiotensin system and its role in physiology and pathology. J Cardiovasc Dev Dis 2019,6(2),14","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","volume":"275","author":"Tipnis S.R.","year":"2000","unstructured":"Tipnis S.R.; Hooper N.M.; Hyde R.; Karran E.; Christie G.; Turner A.J.; A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000,275(43),33238-33243","journal-title":"J Biol Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"Lambert D.W.","year":"2005","unstructured":"Lambert D.W.; Yarski M.; Warner F.J.; Thornhill P.; Parkin E.T.; Smith A.I.; Hooper N.M.; Turner A.J.; Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005,280(34),30113-30119","journal-title":"J Biol Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"Hamming I.","year":"2004","unstructured":"Hamming I.; Timens W.; Bulthuis M.L.; Lely A.T.; Navis G.; van Goor H.; Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004,203(2),631-637","journal-title":"J Pathol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","volume":"12","author":"Hofmann H.","year":"2004","unstructured":"Hofmann H.; P&#xF6;hlmann S.; Cellular entry of the SARS coronavirus. Trends Microbiol 2004,12(10),466-472","journal-title":"Trends Microbiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/cells9040920","volume":"9","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Xu X.; scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and Sertoli cells. Cells 2020,9(4),920","journal-title":"Cells"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"Vickers C.","year":"2002","unstructured":"Vickers C.; Hales P.; Kaushik V.; Dick L.; Gavin J.; Tang J.; Godbout K.; Parsons T.; Baronas E.; Hsieh F.; Acton S.; Patane M.; Nichols A.; Tummino P.; Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002,277(17),14838-14843","journal-title":"J Biol Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-12-0341","volume":"216","author":"Santos R.A.","year":"2013","unstructured":"Santos R.A.; Ferreira A.J.; Verano-Braga T.; Bader M.; Angiotensin- converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013,216(2),R1-R17","journal-title":"J Endocrinol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"Santos R.A.S.","year":"2018","unstructured":"Santos R.A.S.; Sampaio W.O.; Alzamora A.C.; Motta-Santos D.; Alenina N.; Bader M.; Campagnole-Santos M.J.; The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 2018,98(1),505-553","journal-title":"Physiol Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Penninger J.M.; Li Y.; Zhong N.; Slutsky A.S.; Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020,46(4),586-590","journal-title":"Intensive Care Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1139\/cjpp-2013-0488","volume":"92","author":"Parajuli N.","year":"2014","unstructured":"Parajuli N.; Ramprasath T.; Patel V.B.; Wang W.; Putko B.; Mori J.; Oudit G.Y.; Targeting angiotensin- converting enzyme 2 as a new therapeutic target for cardiovascular diseases. Can J Physiol Pharmacol 2014,92(7),558-565","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11897-013-0178-0","volume":"11","author":"Chamsi-Pasha M.A.","year":"2014","unstructured":"Chamsi-Pasha M.A.; Shao Z.; Tang W.H.; Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep 2014,11(1),58-63","journal-title":"Curr Heart Fail Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.102.037382","volume":"303","author":"Raiden S.","year":"2002","unstructured":"Raiden S.; Nahmod K.; Nahmod V.; Semeniuk G.; Pereira Y.; Alvarez C.; Giordano M.; Geffner J.R.; Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J Pharmacol Exp Ther 2002,303(1),45-51","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1507\/endocrj.EJ17-0477","volume":"65","author":"Chen M.","year":"2018","unstructured":"Chen M.; Chen C.; Yuan X.; Chen X.; Zheng F.; Shao L.; Zhang Z.; Angiotensin II aggravates lipopolysaccharide induced human pulmonary microvascular endothelial cells permeability in high glucose status. Endocr J 2018,65(7),717-725","journal-title":"Endocr J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"Gurwitz D.","year":"2020","unstructured":"Gurwitz D.; Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020,81(5),537-540","journal-title":"Drug Dev Res"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14105","volume":"7","author":"Stoll D.","year":"2019","unstructured":"Stoll D.; Yokota R.; Sanches Arag&#xE3;o D.; Casarini D.E.; Both aldosterone and spironolactone can modulate the intracellular ACE\/ANG II\/AT1 and ACE2\/ANG (1-7)\/MAS receptor axes in human mesangial cells. Physiol Rep 2019,7(11)","journal-title":"Physiol Rep"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198144","volume":"13","author":"Ramchand J.","year":"2018","unstructured":"Ramchand J.; Patel S.K.; Srivastava P.M.; Farouque O.; Burrell L.M.; Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One 2018,13(6)","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","volume":"75","author":"Serfozo P.","year":"2020","unstructured":"Serfozo P.; Wysocki J.; Gulua G.; Schulze A.; Ye M.; Liu P.; Jin J.; Bader M.; My&#xF6;h&#xE4;nen T.; Garc&#xED;a-Horsman J.A.; Batlle D.; Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (Angiotensin-converting enzyme 2)-independent. Hypertension 2020,75(1),173-182","journal-title":"Hypertension"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/01.HYP.0000244543.91937.79","volume":"48","author":"Rice G.I.","year":"2006","unstructured":"Rice G.I.; Jones A.L.; Grant P.J.; Carter A.M.; Turner A.J.; Hooper N.M.; Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006,48(5),914-920","journal-title":"Hypertension"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000324521","volume":"34","author":"Wang G.","year":"2011","unstructured":"Wang G.; Lai F.M.; Kwan B.C.; Lai K.B.; Chow K.M.; Li P.K.; Szeto C.C.; Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. Kidney Blood Press Res 2011,34(3),141-149","journal-title":"Kidney Blood Press Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/ndt\/gfv025","volume":"30","author":"Anguiano L.","year":"2015","unstructured":"Anguiano L.; Riera M.; Pascual J.; Valdivielso J.M.; Barrios C.; Betriu A.; Mojal S.; Fern&#xE1;ndez E.; Soler M.J.; Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol Dial Transplant NEFRONA study2015,30(7),1176-1185","journal-title":"Nephrol Dial Transplant"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2019.010501","volume":"29","author":"Gilbert A.","year":"2019","unstructured":"Gilbert A.; Liu J.; Cheng G.; An C.; Deo K.; Gorret A.M.; Qin X.; A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy. Biochem Med (Zagreb) 2019,29(1)","journal-title":"Biochem Med (Zagreb)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","volume":"41","author":"Sama I.E.","year":"2020","unstructured":"Sama I.E.; Ravera A.; Santema B.T.; van Goor H.; Ter Maaten J.M.; Cleland J.G.F.; Rienstra M.; Friedrich A.W.; Samani N.J.; Ng L.L.; Dickstein K.; Lang C.C.; Filippatos G.; Anker S.D.; Ponikowski P.; Metra M.; van Veldhuisen D.J.; Voors A.A.; Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J 2020,41(19),1810-1817","journal-title":"Eur Heart J"},{"key":"ref=45","first-page":"4180","volume":"59","author":"Lin B.","year":"1999","unstructured":"Lin B.; Ferguson C.; White J.T.; Wang S.; Vessella R.; True L.D.; Hood L.; Nelson P.S.; Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999,59(17),4180-4184","journal-title":"Cancer Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-385504-6.00001-4","volume":"99","author":"Antalis T.M.","year":"2011","unstructured":"Antalis T.M.; Bugge T.H.; Wu Q.; Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011,99,1-50","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"12543","DOI":"10.1073\/pnas.0503203102","volume":"102","author":"Matsuyama S.","year":"2005","unstructured":"Matsuyama S.; Ujike M.; Morikawa S.; Tashiro M.; Taguchi F.; Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci USA 2005,102(35),12543-12547","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr&#xFC;ger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N.H.; Nitsche A.; M&#xFC;ller M.A.; Drosten C.; P&#xF6;hlmann S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8","journal-title":"Cell"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"Matsuyama S.","year":"2020","unstructured":"Matsuyama S.; Nao N.; Shirato K.; Kawase M.; Saito S.; Takayama I.; Nagata N.; Sekizuka T.; Katoh H.; Kato F.; Sakata M.; Tahara M.; Kutsuna S.; Ohmagari N.; Kuroda M.; Suzuki T.; Kageyama T.; Takeda M.; Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA 2020,117(13),7001-7003","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/JVI.02202-13","volume":"88","author":"Heurich A.","year":"2014","unstructured":"Heurich A.; Hofmann-Winkler H.; Gierer S.; Liepold T.; Jahn O.; P&#xF6;hlmann S.; TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2014,88(2),1293-1307","journal-title":"J Virol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1096\/fj.202000782","volume":"34","author":"Yan T.","year":"2020","unstructured":"Yan T.; Xiao R.; Lin G.; Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? FASEB J 2020,34(5),6017-6026","journal-title":"FASEB J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41585-020-0319-7","volume":"17","author":"Wang S.","year":"2020","unstructured":"Wang S.; Zhou X.; Zhang T.; Wang Z.; The need for urogenital tract monitoring in COVID-19. Nat Rev Urol 2020,17(6),314-315","journal-title":"Nat Rev Urol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/cmi.2014.38","volume":"11","author":"Zhao S.","year":"2014","unstructured":"Zhao S.; Zhu W.; Xue S.; Han D.; Testicular defense systems: immune privilege and innate immunity. Cell Mol Immunol 2014,11(5),428-437","journal-title":"Cell Mol Immunol"},{"key":"ref=54","author":"Ma L.","year":"2020","unstructured":"Ma L.; Xie W.; Li D.; Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study. medRxiv 2020 www.medrxiv.org\/content\/10.1101\/2020.03.21.20037267v2","journal-title":"medRxiv"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.fertnstert.2020.04.024","volume":"113","author":"Pan F.","year":"2020","unstructured":"Pan F.; Xiao X.; Guo J.; No evidence of SARS-CoV-2 in semen of males recovering from COVID-19. Fertil Steril 2020,113(6),1135-1139","journal-title":"Fertil Steril"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"Wu C.","year":"2020","unstructured":"Wu C.; Chen X.; Cai Y.; Xia J.; Zhou X.; Xu S.; Huang H.; Zhang L.; Zhou X.; Du C.; Zhang Y.; Song J.; Wang S.; Chao Y.; Yang Z.; Xu J.; Zhou X.; Chen D.; Xiong W.; Xu L.; Zhou F.; Jiang J.; Bai C.; Zheng J.; Song Y.; Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020,180(7),934-943","journal-title":"JAMA Intern Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"Guan W.J.","year":"2020","unstructured":"Guan W.J.; Ni Z.Y.; Hu Y.; Liang W.H.; Ou C.Q.; He J.X.; Liu L.; Shan H.; Lei C.L.; Hui D.S.C.; Du B.; Li L.J.; Zeng G.; Yuen K.Y.; Chen R.C.; Tang C.L.; Wang T.; Chen P.Y.; Xiang J.; Li S.Y.; Wang J.L.; Liang Z.J.; Peng Y.X.; Wei L.; Liu Y.; Hu Y.H.; Peng P.; Wang J.M.; Liu J.Y.; Chen Z.; Li G.; Zheng Z.J.; Qiu S.Q.; Luo J.; Ye C.J.; Zhu S.Y.; Zhong N.S.; China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med China Medical Treatment Expert Group for Covid-192020,382(18),1708-1720","journal-title":"N Engl J Med"},{"key":"ref=58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"Fang L.","year":"2020","unstructured":"Fang L.; Karakiulakis G.; Roth M.; Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020,8(4)","journal-title":"Lancet Respir Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"Ferrario C.M.","year":"2005","unstructured":"Ferrario C.M.; Jessup J.; Chappell M.C.; Averill D.B.; Brosnihan K.B.; Tallant E.A.; Diz D.I.; Gallagher P.E.; Effect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005,111(20),2605-2610","journal-title":"Circulation"},{"key":"ref=60","first-page":"1280","volume":"19","author":"Walters T.E.","year":"2017","unstructured":"Walters T.E.; Kalman J.M.; Patel S.K.; Mearns M.; Velkoska E.; Burrell L.M.; Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace 2017,19(8),1280-1287","journal-title":"Europace"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"Kuba K.","year":"2005","unstructured":"Kuba K.; Imai Y.; Rao S.; Gao H.; Guo F.; Guan B.; Huan Y.; Yang P.; Zhang Y.; Deng W.; Bao L.; Zhang B.; Liu G.; Wang Z.; Chappell M.; Liu Y.; Zheng D.; Leibbrandt A.; Wada T.; Slutsky A.S.; Liu D.; Qin C.; Jiang C.; Penninger J.M.; A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005,11(8),875-879","journal-title":"Nat Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"m40","DOI":"10.1136\/bmj.m406","volume":"368","author":"Phadke M.","year":"2020","unstructured":"Phadke M.; Saunik S.; Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections - novel mode of treatment. Response to the emerging novel coronavirus outbreak. BMJ 2020,368,m40","journal-title":"BMJ"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"Zheng Y.Y.","year":"2020","unstructured":"Zheng Y.Y.; Ma Y.T.; Zhang J.Y.; Xie X.; COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020,17(5),259-260","journal-title":"Nat Rev Cardiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Imai Y.","year":"2005","unstructured":"Imai Y.; Kuba K.; Rao S.; Huan Y.; Guo F.; Guan B.; Yang P.; Sarao R.; Wada T.; Leong-Poi H.; Crackower M.A.; Fukamizu A.; Hui C.C.; Hein L.; Uhlig S.; Slutsky A.S.; Jiang C.; Penninger J.M.; Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005,436(7047),112-116","journal-title":"Nature"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1038\/ncomms4594","volume":"5","author":"Zou Z.","year":"2014","unstructured":"Zou Z.; Yan Y.; Shu Y.; Gao R.; Sun Y.; Li X.; Ju X.; Liang Z.; Liu Q.; Zhao Y.; Guo F.; Bai T.; Han Z.; Zhu J.; Zhou H.; Huang F.; Li C.; Lu H.; Li N.; Li D.; Jin N.; Penninger J.M.; Jiang C.; Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 2014,5,3594","journal-title":"Nat Commun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1038\/srep07027","volume":"4","author":"Yang P.","year":"2014","unstructured":"Yang P.; Gu H.; Zhao Z.; Wang W.; Cao B.; Lai C.; Yang X.; Zhang L.; Duan Y.; Zhang S.; Chen W.; Zhen W.; Cai M.; Penninger J.M.; Jiang C.; Wang X.; Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014,4,7027","journal-title":"Sci Rep"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"Li J.","year":"2020","unstructured":"Li J.; Wang X.; Chen J.; Zhang H.; Deng A.; Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 2020,5(7),825-830","journal-title":"JAMA Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007621","volume":"382","author":"Mehra M.R.","year":"2020","unstructured":"Mehra M.R.; Desai S.S.; Kuy S.; Henry T.D.; Patel A.N.; Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020,382(25)","journal-title":"N Engl J Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"Mancia G.","year":"2020","unstructured":"Mancia G.; Rea F.; Ludergnani M.; Apolone G.; Corrao G.; Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020,382(25),2431-2440","journal-title":"N Engl J Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"Reynolds H.R.","year":"2020","unstructured":"Reynolds H.R.; Adhikari S.; Pulgarin C.; Troxel A.B.; Iturrate E.; Johnson S.B.; Hausvater A.; Newman J.D.; Berger J.S.; Bangalore S.; Katz S.D.; Fishman G.I.; Kunichoff D.; Chen Y.; Ogedegbe G.; Hochman J.S.; Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020,382(25),2441-2448","journal-title":"N Engl J Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"Fosb&#xF8;l E.L.","year":"2020","unstructured":"Fosb&#xF8;l E.L.; Butt J.H.; &#xD8;stergaard L.; Andersson C.; Selmer C.; Kragholm K.; Schou M.; Phelps M.; Gislason G.H.; Gerds T.A.; Torp-Pedersen C.; K&#xF8;ber L.; Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 2020,324(2),168-177","journal-title":"JAMA"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7326\/M20-1515","volume":"173","author":"Mackey K.","year":"2020","unstructured":"Mackey K.; King V.J.; Gurley S.; Kiefer M.; Liederbauer E.; Vela K.; Sonnen P.; Kansagara D.; Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med 2020,173(3),195-203","journal-title":"Ann Intern Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.kint.2020.04.009","volume":"97","author":"Alhenc-Gelas F.","year":"2020","unstructured":"Alhenc-Gelas F.; Drueke T.B.; Blockade of SARS-CoV-2 infection by recombinant soluble ACE2. Kidney Int 2020,97(6),1091-1093","journal-title":"Kidney Int"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"Monteil V.","year":"2020","unstructured":"Monteil V.; Kwon H.; Prado P.; Hagelkr&#xFC;ys A.; Wimmer R.A.; Stahl M.; Leopoldi A.; Garreta E.; Hurtado Del Pozo C.; Prosper F.; Romero J.P.; Wirnsberger G.; Zhang H.; Slutsky A.S.; Conder R.; Montserrat N.; Mirazimi A.; Penninger J.M.; Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020,181(4),905-913.e7","journal-title":"Cell"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1001\/jama.2020.8946","volume":"323","author":"Patel A.B.","year":"2020","unstructured":"Patel A.B.; Verma A.; Nasal ACE2 levels and COVID-19 in children. JAMA 2020,323(23),2386-2387","journal-title":"JAMA"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.mayocp.2020.03.026","volume":"95","author":"Sanchis-Gomar F.","year":"2020","unstructured":"Sanchis-Gomar F.; Lavie C.J.; Perez-Quilis C.; Henry B.M.; Lippi G.; Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019. Mayo Clin Proc 2020,95(6),1222-1230","journal-title":"Mayo Clin Proc"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Schroeder S.; Kleine-Weber H.; M&#xFC;ller M.A.; Drosten C.; P&#xF6;hlmann S.; Nafamostat mesylate blocks activation of SARS- CoV-2: New treatment option for COVID-19. Antimicrob Agents Chemother 2020,64(6),e00754-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3346\/jkms.2011.26.7.945","volume":"26","author":"Han S.J.","year":"2011","unstructured":"Han S.J.; Kim H.S.; Kim K.I.; Whang S.M.; Hong K.S.; Lee W.K.; Lee S.H.; Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci 2011,26(7),945-950","journal-title":"J Korean Med Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","volume":"92","author":"Gao Y.","year":"2020","unstructured":"Gao Y.; Li T.; Han M.; Li X.; Wu D.; Xu Y.; Zhu Y.; Liu Y.; Wang X.; Wang L.; Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020,92(7),791-796","journal-title":"J Med Virol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/jmv.25783","volume":"92","author":"Wan S.","year":"2020","unstructured":"Wan S.; Xiang Y.; Fang W.; Zheng Y.; Li B.; Hu Y.; Lang C.; Huang D.; Sun Q.; Xiong Y.; Huang X.; Lv J.; Luo Y.; Shen L.; Yang H.; Huang G.; Yang R.; Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020,92(7),797-806","journal-title":"J Med Virol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/jch.13917","volume":"22","author":"Kario K.","year":"2020","unstructured":"Kario K.; Morisawa Y.; Sukonthasarn A.; Turana Y.; Chia Y.C.; Park S.; Wang T.D.; Chen C.H.; Tay J.C.; Li Y.; Wang J.G.; COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens (Greenwich) Hypertension Cardiovascular Outcome Prevention, Evidence in Asia (HOPE Asia) Network2020,22(7),1109-1119","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573402117666210121100201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/190533\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573402117666210121100201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T04:02:51Z","timestamp":1659931371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/190533\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402117666210121100201","relation":{},"ISSN":["1573-4021"],"issn-type":[{"value":"1573-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}